| Message: | Bremelanotide (formerly PT-141) is a compound under drug development by Palatin Technologies as a treatment for female sexual dysfunction, hemorrhagic shock and reperfusion injury. It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limiting ischemia. It was originally tested for intranasal administration in treating female sexual dysfunction but this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. As of March, 2012, Palatin is conducting a human Phase 2B study using a new subcutaneous drug delivery system that appears to have little effect on blood pressure.
Product Name PT141
Cas No. 32780-32-8
Molecular Formula C50H68N14O10
Molecular Weight 1025.2
Purity (HPLC) 98.0%min.
Appearance White powder
Single Impurity (HPLC) 1.0%max
Amino Acid Composition ±10% of theoretical
Peptide Content (N%) ≥80.0%
Water Content(Karl Fischer) ≤6.0%
Acetate Content (HPIC) ≤15.0%
MS(ESI) Consistent
Mass Balance 95.0~105.0% |
my account
